Skip to main content
TipRanks
Go Ultimate75% OFF

Eden Research (EDEN) AI Stock Analysis

13 Followers
GB:EDEN

Eden Research

(LSE:EDEN)

Select Model
Rating:52Neutral
Price Target:GBX 3.00â–¼(-6.25% Downside)
Action:reiterated
Date:11/17/26

The score is primarily constrained by persistent losses and negative cash generation. Favorable technical positioning and strong revenue growth provide support, but the negative P/E and lack of dividend income reinforce the need for improved profitability and cash flow.

Positive Factors
Conservative balance sheetVery low leverage gives Eden financial resilience while it remains loss-making, because limited debt reduces interest and refinancing pressure. The sizeable equity base relative to debt also preserves flexibility to fund development and commercialisation before profitability is achieved.
Negative Factors
Persistent operating lossesRecurring operating and net losses show that Eden has not yet converted product activity into sustainable profitability. Continued losses can constrain reinvestment, weaken returns on shareholder capital, and increase the importance of successful commercial execution and eventual operating leverage.

Eden Research (EDEN) vs. iShares MSCI United Kingdom ETF (EWC)

-25%0%25%50%75%100%125%GB:EDEN+45.45%EWC+18.67%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 25.71M
Dividend Yield
―
Average Volume (3M)
730.05K
Price to Earnings (P/E)
-8.9
Beta (1Y)
1.23
Revenue Growth
―
EPS Growth
―
Country
UK
Employees
23
Sector
Basic Materials
Sector Strength
61
Industry
Agricultural Inputs

Eden Research Business Overview & Revenue Model

Company Description

Eden BioSolutions Plc offers sustainable solutions for crop protection, animal health and consumer products in the United Kingdom and rest of Europe. The firm provides various plant protection products, such as foliar disease control, soil pest, prot...

How the Company Makes Money

Eden Research primarily makes money by commercialising its bio-based crop protection products and technology through licensing and distribution arrangements with partners. Revenue is generated mainly from (1) product sales and related partner purchas...

Eden Research Financial Statement Overview

Summary

Revenue growth and low borrowing support the score, but persistent operating losses, negative equity trend, and ongoing negative operating and free cash flow materially weaken financial performance.

Income Statement

42Neutral

Balance Sheet

63Positive

Cash Flow

32Negative
Financial statement breakdown
BreakdownTTMMar 2026Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.62M3.88M4.30M3.19M1.83M1.23M
Gross Profit1.39M1.14M1.87M1.77M207.14K28.32K
EBITDA-1.68M-1.56M-1.59M-6.24M-1.83M-2.72M
Net Income-2.35M-1.96M-1.91M-6.49M-2.24M-2.79M
Balance Sheet
Total Assets13.46M16.34M15.41M16.59M12.91M15.03M
Cash, Cash Equivalents and Short-Term Investments1.85M1.52M3.67M7.41M1.99M3.83M
Total Debt571.86K671.91K168.73K229.77K355.32K398.35K
Total Liabilities2.85M3.91M3.57M3.05M2.17M2.20M
Stockholders Equity10.58M12.42M11.82M13.52M10.72M12.80M
Cash Flow
Free Cash Flow-710.00K-2.45M-3.60M-1.80M-1.74M-3.34M
Operating Cash Flow-209.90K-2.44M-1.01M-1.70M-683.10K-1.62M
Investing Cash Flow-2.72M-2.41M-2.48M-1.72M-1.05M-1.73M
Financing Cash Flow-150.87K2.64M-155.53K8.90M-150.35K-90.39K

Eden Research Technical Analysis

Technical Analysis SentimentPositive
Last Price3.20

Price Trends

50DMA2.55Positive
100DMA2.57Positive
200DMA2.98Positive

Market Momentum

MACD0.22Positive
RSI57.65Neutral
STOCH37.12Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EDEN, the sentiment is Positive. The current price of 3.20 is above the 20-day moving average (MA) of 3.01, above the 50-day MA of 2.55, and above the 200-day MA of 2.98, indicating a bullish trend. The MACD of 0.22 indicates Positive momentum. The RSI at 57.65 is Neutral, neither overbought nor oversold. The STOCH value of 37.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:EDEN.

Eden Research Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

GB:EDEN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:ELMGB:ELM73OutperformGBP 1.09B19.6111.29%1.73%-11.73%―
GB:CRDAGB:CRDA66NeutralGBP 5.34B67.573.65%2.90%3.36%-43.08%
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
GB:SYNTGB:SYNT60NeutralGBP 196.40M-1.64-13.27%―-4.98%-43.98%
GB:ITXGB:ITX56NeutralGBP 26.10M-27.43-15.42%―57.55%2.94%
GB:EDENGB:EDEN52NeutralGBP 25.71M-8.89-16.16%―――

* Basic Materials Sector Average

Performance Comparison

-50%0%50%100%GB:EDENGB:CRDAGB:ELMGB:ITXGB:SYNTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:EDEN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:EDENEden Research3.201.0548.84%
GB:CRDACroda International3822.001211.4546.41%
GB:ELMElementis plc192.6040.6426.74%
GB:ITXItaconix plc193.5071.0057.96%
GB:SYNTSynthomer plc119.8069.60138.65%

Eden Research Corporate Events

Business Operations and Strategy

Eden BioSolutions targets partnerships at global biocontrol summit

Positive
Oct 19, 2026

Eden BioSolutions will send its chief executive Sean Smith, chief financial officer Alex Abrey and other commercial team members to the Annual Biocontrol Industry Meeting in Basel from 20 to 22 October 2026. The event is a key gathering for the globa...

Business Operations and StrategyShareholder Meetings

Eden BioSolutions plans investor update as sustainable biopesticide portfolio grows

Positive
Oct 6, 2026

Eden BioSolutions plc, a specialist in sustainable biopesticides and biocontrol technologies, serves global agriculture and related sectors with plant‑based crop protection products and plastic‑free microencapsulation solutions. Its commercialised of...

Business Operations and Strategy

Eden Research Rebrands as Eden BioSolutions to Sharpen Biopesticide Focus

Positive
Oct 1, 2026

Eden BioSolutions, a UK-listed leader in sustainable biopesticides and biocontrol technologies, serves global crop protection, animal health and consumer markets with plant-derived products aimed at high-value fruits, vegetables and seed treatments....

Business Operations and StrategyShareholder Meetings

Eden Research Wins AGM Backing and Rebrands as Eden BioSolutions

Positive
Sep 29, 2026

Eden Research plc, the AIM-quoted biopesticides specialist, has secured strong shareholder backing at its Annual General Meeting, with all resolutions passed, including the reappointment of board members and authorities related to share issuance and...

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings

Eden Research uses AGM to showcase regulatory wins and expanding biopesticide pipeline

Positive
Sep 29, 2026

Eden Research’s AGM statement highlights continued momentum in building its position as an emerging leader in biological crop protection, with fresh commercial and regulatory milestones for its existing products. Recent progress includes California a...

Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance

Eden Research Wins EPA Label Expansion for Mevalone in Key U.S. Market

Positive
Sep 28, 2026

Eden Research, the only UK-listed company focused solely on biopesticides for sustainable agriculture, develops terpene-based crop protection products and plastic-free Sustaine microencapsulation for use on high-value fruits, vegetables and other cro...

Business Operations and StrategyExecutive/Board Changes

Eden Research Grants Long-Term Incentive Options Tied to Shareholder Returns and Revenue Targets

Positive
Sep 17, 2026

Eden Research has granted 33,737,659 options over new ordinary shares under its Long Term Incentive Plan for calendar year 2025, aligning staff rewards with future performance. The awards include 7,101,189 options for chief executive Sean Smith, 5,33...

Business Operations and StrategyFinancial DisclosuresShareholder Meetings

Eden Research posts 2026 accounts and sets date for AGM

Positive
Sep 7, 2026

Eden Research plc, the AIM‑quoted biopesticides and biocontrol specialist, has published its Annual Report and Accounts for the fifteen‑month period to 31 March 2026 and circulated the Notice of its upcoming Annual General Meeting. The AGM is schedul...

Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance

Eden Research boosts revenue and global approvals as losses widen

Positive
Aug 26, 2026

Eden Research reported preliminary results for the 15 months to 31 March 2026, with revenue rising to £4.9 million but operating losses widening to £2.9 million and cash falling to £1.5 million. The company completed a £10.8 million fundraise around...

Business Operations and StrategyFinancial Disclosures

Eden Research sets date for 2026 preliminary results and investor briefing

Positive
Aug 25, 2026

Eden Research plc, a UK-listed leader in sustainable biopesticides and biocontrol technologies, develops plant-derived crop protection products and a biodegradable microencapsulation platform for global agriculture and related markets. Its key offeri...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026